Case Report: Off Label Utilization of Topiramate and Metformin in Patients With BMI ≥50 kg/m2 Prior to Bariatric Surgery
FDA approved anti-obesity medications may not be cost effective for patients struggling with pre-operative weight loss prior to bariatric surgery. Metformin, a biguanide, and Topiramate, a carbonic anhydrase inhibitor, both cost effective medications, have demonstrated weight loss when used for the...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-02-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2021.588016/full |
| _version_ | 1818645503996329984 |
|---|---|
| author | Cetin Sari Richard L. Seip Richard L. Seip Devika Umashanker Devika Umashanker |
| author_facet | Cetin Sari Richard L. Seip Richard L. Seip Devika Umashanker Devika Umashanker |
| author_sort | Cetin Sari |
| collection | DOAJ |
| description | FDA approved anti-obesity medications may not be cost effective for patients struggling with pre-operative weight loss prior to bariatric surgery. Metformin, a biguanide, and Topiramate, a carbonic anhydrase inhibitor, both cost effective medications, have demonstrated weight loss when used for the treatment of type 2 diabetes or seizures, respectively. The aim of the three cases is to demonstrate the clinical utility of topiramate and metformin for preoperative weight loss in patients with a body mass index (BMI) ≥ 50 kg/m2 prior to bariatric surgery who are unable to follow the bariatric nutritional prescription due to a dysregulated appetite system Each patient was prescribed metformin and/or topiramate in an off-label manner in conjunction with lifestyle modifications and achieved >8% total body weight loss during the preoperative period. |
| first_indexed | 2024-12-17T00:31:47Z |
| format | Article |
| id | doaj.art-ba5eee0bb0914c48ab41924a365d7cd2 |
| institution | Directory Open Access Journal |
| issn | 1664-2392 |
| language | English |
| last_indexed | 2024-12-17T00:31:47Z |
| publishDate | 2021-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj.art-ba5eee0bb0914c48ab41924a365d7cd22022-12-21T22:10:17ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922021-02-011210.3389/fendo.2021.588016588016Case Report: Off Label Utilization of Topiramate and Metformin in Patients With BMI ≥50 kg/m2 Prior to Bariatric SurgeryCetin Sari0Richard L. Seip1Richard L. Seip2Devika Umashanker3Devika Umashanker4Metabolic and Bariatric Surgery Center, Hartford Hospital, Hartford, CT, United StatesMetabolic and Bariatric Surgery Center, Hartford Hospital, Hartford, CT, United StatesDivision of Research Data Management, Hartford Hospital, Hartford, CT, United StatesMetabolic and Bariatric Surgery Center, Hartford Hospital, Hartford, CT, United StatesMedical Weight Management Program, Hartford Hospital, Hartford, CT, United StatesFDA approved anti-obesity medications may not be cost effective for patients struggling with pre-operative weight loss prior to bariatric surgery. Metformin, a biguanide, and Topiramate, a carbonic anhydrase inhibitor, both cost effective medications, have demonstrated weight loss when used for the treatment of type 2 diabetes or seizures, respectively. The aim of the three cases is to demonstrate the clinical utility of topiramate and metformin for preoperative weight loss in patients with a body mass index (BMI) ≥ 50 kg/m2 prior to bariatric surgery who are unable to follow the bariatric nutritional prescription due to a dysregulated appetite system Each patient was prescribed metformin and/or topiramate in an off-label manner in conjunction with lifestyle modifications and achieved >8% total body weight loss during the preoperative period.https://www.frontiersin.org/articles/10.3389/fendo.2021.588016/fullgeneric weight loss medicationspreoperative weight lossanti-obesity pharmacotherapypre-surgerysuper obesitymedical weight loss |
| spellingShingle | Cetin Sari Richard L. Seip Richard L. Seip Devika Umashanker Devika Umashanker Case Report: Off Label Utilization of Topiramate and Metformin in Patients With BMI ≥50 kg/m2 Prior to Bariatric Surgery Frontiers in Endocrinology generic weight loss medications preoperative weight loss anti-obesity pharmacotherapy pre-surgery super obesity medical weight loss |
| title | Case Report: Off Label Utilization of Topiramate and Metformin in Patients With BMI ≥50 kg/m2 Prior to Bariatric Surgery |
| title_full | Case Report: Off Label Utilization of Topiramate and Metformin in Patients With BMI ≥50 kg/m2 Prior to Bariatric Surgery |
| title_fullStr | Case Report: Off Label Utilization of Topiramate and Metformin in Patients With BMI ≥50 kg/m2 Prior to Bariatric Surgery |
| title_full_unstemmed | Case Report: Off Label Utilization of Topiramate and Metformin in Patients With BMI ≥50 kg/m2 Prior to Bariatric Surgery |
| title_short | Case Report: Off Label Utilization of Topiramate and Metformin in Patients With BMI ≥50 kg/m2 Prior to Bariatric Surgery |
| title_sort | case report off label utilization of topiramate and metformin in patients with bmi ≥50 kg m2 prior to bariatric surgery |
| topic | generic weight loss medications preoperative weight loss anti-obesity pharmacotherapy pre-surgery super obesity medical weight loss |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2021.588016/full |
| work_keys_str_mv | AT cetinsari casereportofflabelutilizationoftopiramateandmetformininpatientswithbmi50kgm2priortobariatricsurgery AT richardlseip casereportofflabelutilizationoftopiramateandmetformininpatientswithbmi50kgm2priortobariatricsurgery AT richardlseip casereportofflabelutilizationoftopiramateandmetformininpatientswithbmi50kgm2priortobariatricsurgery AT devikaumashanker casereportofflabelutilizationoftopiramateandmetformininpatientswithbmi50kgm2priortobariatricsurgery AT devikaumashanker casereportofflabelutilizationoftopiramateandmetformininpatientswithbmi50kgm2priortobariatricsurgery |